Clinical Trials Logo

Clostridium Difficile Infections clinical trials

View clinical trials related to Clostridium Difficile Infections.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06398379 Not yet recruiting - Clinical trials for Clostridium Difficile Infections

Virus as Treatment of C. Difficile Infection (VISION)

VISION
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Fecal Virome Transplantation (FVT) has in small studies shown benefit in the treatment of recurrent C. difficile infection. In the VISION study we will treat patients with recurrent C. difficile infection with FVT capsules and compare the treatment with Fecal Microbiota Transplantation (FMT) capsules. Both will be following af standard treatment of antibiotics (Vancomycin)

NCT ID: NCT06237452 Not yet recruiting - Clinical trials for Clostridium Difficile

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

RESTORATiVE303
Start date: April 2024
Phase: Phase 3
Study type: Interventional

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).

NCT ID: NCT06107569 Not yet recruiting - Clinical trials for Clostridium Difficile Infections

Treatment of CDI and Recurrence With Fecal Microbiota Transplant Using Promicrobioma

Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

The increasing inappropriate use of antimicrobials, in addition to increasing selective pressure and inducing environmental resistance, is also a risk factor for the development of Clostridioides difficile infection (CDI). The intestinal microbiota is mainly composed of the phyla Firmicutes, Bacteroidetes, Acinobacteria, Proteobacteria, Fusobacteria and Verrucomicrobia, and more than 90% of the phylum Firmicutes is composed of Clostridium spp. (two). The inappropriate use of antimicrobials initiates a process of dysregulation of the microbiome, called dysbiosis, and it is from the selection of genera and species of bacteria that will dominate the intestine that pseudomembranous colitis can set in with an increased burden of Clostridioides difficile, a gram positive, anaerobic, spore-forming, that produces two enterotoxins, toxin A and toxin.

NCT ID: NCT05256693 Not yet recruiting - Clinical trials for Stem Cell Transplant Complications

Prevention of C.Difficile Infections With Oral Vancomycine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

VANCALLO
Start date: March 2022
Phase: Phase 3
Study type: Interventional

Clostridium difficile (CD) infection are an important cause of morbi-mortality in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT). The VANCALLO trial aims at evaluating oral vancomycine reducing the risk of CD infection relying on a placebo controlled 1:1 randomized design, including one interim analysis.